Arrowhead Pharmaceuticals Target Price

Analysts' average 12-month price target for Arrowhead Pharmaceuticals is $100.

Get informed when a big investor buys or sells

+ Follow

Share Price

$87.9

Average Target Price

$103.78

18.1% upside

9 analysts in the last 4 months

High: $126 | Low: $46

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-08-06	H.C. Wainwright	$120	36.5% upside
2026-08-05	Stifel Nicolaus	$104	18.3% upside
2026-07-27	H.C. Wainwright	$115	30.8% upside
2026-07-23	Morgan Stanley	$120	36.5% upside
2026-07-23	Piper SandlerEdward Tenthoff	$126	43.3% upside
2026-07-22	Chardan CapitalKeay Nakae	$115	30.8% upside
2026-07-13	Stifel NicolausJames Condulis	$98	11.5% upside
2026-05-13	Bernstein	$46	47.7% downside
2026-05-08	Chardan Capital	$90	2.4% upside
2026-04-21	Morgan Stanley	$100	13.8% upside
2026-02-06	Morgan Stanley	$78	11.3% downside
2026-01-27	Robert W. Baird	$81	7.8% downside
2026-01-21	H.C. Wainwright	$100	13.8% upside
2026-01-13	UBS	$110	25.1% upside
2026-01-13	Piper Sandler	$110	25.1% upside
2026-01-07	Morgan Stanley	$81	7.8% downside
2026-01-07	Chardan Capital	$80	9% downside
2026-01-02	Tudor PickeringWilliam Pickering	$35	60.2% downside
2025-12-31	Bernstein	$35	60.2% downside
2025-12-17	Piper SandlerEdward Tenthoff	$100	13.8% upside
2025-12-11	RBC Capital	$80	9% downside
2025-12-02	H.C. Wainwright	$85	3.3% downside
2025-11-26	Morgan Stanley	$48	45.4% downside
2024-11-29	BernsteinWilliam Pickering	$24	72.7% downside
2024-11-27	Loop Capital MarketsKeay Nakae	$29.97	65.9% downside
2024-09-03	CitigroupDavid Lebowitz	$27	69.3% downside
2024-07-05	H.C. WainwrightPatrick Trucchio	$29.97	65.9% downside
2024-06-05	Goldman SachsAndrea Tan	$31	64.7% downside
2024-05-30	RBC CapitalLuca Issi	$24.98	71.6% downside
2023-02-07	RBC Capital	$38.46	56.2% downside
2023-02-07	Piper Sandler	$52	40.8% downside
2022-12-06	H.C. Wainwright	$44.96	48.9% downside
2022-11-29	Jefferies	$37.47	57.4% downside
2022-11-29	Morgan Stanley	$37	57.9% downside
2022-11-29	Leerink Partners	$31	64.7% downside
2022-01-19	Goldman SachsMadhu Kumar	$85	3.3% downside

Arrowhead Pharmaceuticals (ARWR) FAQ

Arrowhead Pharmaceuticals (ARWR) currently reports a target price of $100. Use the charts on this page to explore Arrowhead Pharmaceuticals's target price history and peer comparisons.

Analysts' average 12-month price target for Arrowhead Pharmaceuticals is $100, about 18.1% upside from the current share price of $87.9. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $100, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Arrowhead Pharmaceuticals, and consider following ARWR for alerts when major investors trade the stock.

Arrowhead Pharmaceuticals is classified in the Healthcare sector. On target price, it currently shows $100. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ARWR with unrelated industries.